FDA Investigating the Risk of Cardiovascular Events in Men Using Prescription Testosterone Products
(EMAILWIRE.COM, February 28, 2014 ) New York, NY -- ClassAction.org is alerting consumers to reports that the FDA is investigating the risk of cardiovascular events in men using prescription testosterone products. According to two recent studies, testosterone therapies may be linked to an increased risk of stroke, heart attack and death. Following the publication of this research, the FDA said that it would continue to evaluate the information from these studies and other available data and later announce its final conclusions. For more information, visit http://www.classaction.org/testosterone-therapy today.
On January 31, 2014, the FDA published a safety announcement to alert the public that it would be investigating the risk of heart attack, stroke and death in men using prescription testosterone products. The investigation was spurred by two recent studies, published in the medical journal PLOS ONE and The Journal of the American Medical Association (JAMA), which both found a link between prescription testosterone and serious cardiovascular events. Researchers in the JAMA study found that men using prescription testosterone therapies were at a 30 percent increased risk of heart attack, stroke and death. Furthermore, the PLOS ONE study shed some light on groups of men who may be at the highest risk for serious cardiovascular events: middle-aged men with a history of heart disease and men ages 65 and older. According to the study, these men were tracked for a year prior to receiving prescription testosterone and the three months following testosterone therapy. Researchers found that the men suffered from twice as many heart attacks and ischemic strokes after using prescriptions to treat low testosterone.
In its safety announcement, the FDA stressed that prescription testosterone therapies have only been approved for use in men with a medical condition that affects their levels of testosterone, including certain genetic problems. The agency suggested that healthcare professionals consider whether the benefits of prescription testosterone outweigh its risks and advised that men using prescription testosterone therapies should not stop using the treatments before speaking with their doctors. While the agency said it has not reached any conclusions yet, it is continuing to review available data on the risks of prescription testosterone.
Following the FDAs announcement, several lawsuits were filed against the maker of the prescription testosterone product AndroGel. These lawsuits allege that men who used AndroGel suffered heart attacks, strokes or ischemic strokes, and that Abbott Laboratories failed to adequately warn physicians and patients that its testosterone product could cause serious cardiovascular events. In light of these allegations, the attorneys working with ClassAction.org are looking to hear from men who used prescription testosterone therapies. If you or a loved one suffered an injury after using prescription testosterone, contact us today by visiting http://www.classaction.org/testosterone-therapy.
Class Action.org is dedicated to protecting consumers and investors in class actions and complex litigation throughout the United States. Class Action.org keeps consumers informed about product alerts, recalls, and emerging litigation and helps them take action against the manufacturers of defective products, drugs, and medical devices. Information about consumer fraud issues and environmental hazards is also available on the site. Visit ClassAction.org today for a no cost, no obligation case evaluation and information about your consumer rights.
firstname.lastname@example.org This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php. Source: EmailWire.Com